M&A Deal Summary

Incyte Acquires Villaris

On October 3, 2022, Incyte acquired life science company Villaris for 1.4B USD

Acquisition Highlights
  • This is Incyte’s 3rd transaction in the Life Science sector.
  • This is Incyte’s largest (disclosed) transaction.
  • This is Incyte’s 4th transaction in the United States.
  • This is Incyte’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2022-10-03
Target Villaris
Sector Life Science
Buyer(s) Incyte
Deal Type Add-on Acquisition
Deal Value 1.4B USD
Advisor(s) PJT Partners, Inc. (Financial)

Target

Villaris

Cary, North Carolina, United States
website
Villaris is an asset-centric biopharmaceutical company that developed a potentially transformational new treatment to improve the lives of people living with vitiligo. Villaris was formed in 2019 and is based in Cary, North Carolina.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Incyte

Wilmington, Delaware, United States

website

Category Company
Founded 1991
Sector Life Science
Employees2,094
Revenue 3.0B USD (2021)
DESCRIPTION

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. Incyte was founded in 1991 and is based in Wilmington, Delaware.

DEAL STATS #
Overall 4 of 5
Sector (Life Science) 3 of 4
Type (Add-on Acquisition) 3 of 4
State (North Carolina) 1 of 1
Country (United States) 4 of 5
Year (2022) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-05-09 Ariad Pharmaceuticals - Iclusig Business

Cambridge, Massachusetts, United States

Ariad Pharmaceuticals - Iclusig Business is a kinase inhibitor. Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

Buy $140M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-04-23 Escient Pharmaceuticals

San Diego, California, United States

Escient Pharmaceuticals is a clinical-stage company that develops novel therapeutics to address various neurosensory-inflammatory disorders. The company’s pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for treating various mast cell-mediated disorders and MRGPRX4 for cholestatic pruritus. Escient Pharmaceuticals is based in San Diego, California.

Buy -
Mergr

Product

Company

Legal